AzTrials
AzTrials

Atrial Fibrillation RecurrenceNCT06977516

Atrial Fibrillation Recurrence Prediction

An observational study of Atrial Fibrillation Recurrence, run by The Fourth Affiliated Hospital of Zhejiang University School of Medicine at 5 sites in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

We aimed to develop an dual-branch deep learning network that integrates feature representations extracted from medical texts using large language models, with structured data features derived from perioperative records of AF ablation patients. Read more about this study

Who is it for?
Ages 18 to 90 years
Conditions the study is for
Atrial Fibrillation Recurrence
How many people
2,508 participants
Where
5 sitesChina
Study dates
15 Apr 2025to 31 Aug 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: We plan to extract data from patients diagnosed with atrial fibrillation who underwent their first atrial fibrillation ablation at the Fourth Affiliated Hospital of Zhejiang University School of Medicine, Taizhou Hospital of Zhejiang Province, the Affiliated Hospital of Yunnan University, Jinhua People's Hospital, and Beilun District Hospital. The collected data will include the patient's general information, laboratory tests, preoperative dynamic electrocardiogram text modality, echocardiogram text modality, and surgical procedure. The primary observation endpoint will be atrial fibrillation recurrence (defined as the detection of a persistent atrial arrhythmia lasting more than 30 seconds on ECG or dynamic ECG after ablation), with a follow-up period extending until March 2025.

Who may be able to join

None listed.

Who cannot join

  • Repeat ablation procedures;
  • Valvular AF or AF with NYHA class IV heart failure.
  • Missing Holter ECG or preoperative echocardiography data;
  • Loss to follow-up after ablation;

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

China5 sites
  • Jinhua People's Hospital

    Jinhua, Zhejiang, 321000

  • The Affiliated Hospital of Yunnan University

    Kunming, Yunnan, 650000

  • Beilun District People's Hospital

    Ningbo, Zhejiang, 315800

  • Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

    Taizhou, Zhejiang, 317000

  • The Fourth Affiliated Hospital of Zhejiang University School of Medicine

    Yiwu, Zhejiang, 322000

Other trials in China

About this study

Official title: A Dual-Branch Deep Learning Network Integrating Structured Data and Large Language Model-Based Medical Text Features for Atrial Fibrillation Recurrence Prediction: A Retrospective, Multicenter Study

We aimed to develop an dual-branch deep learning network that integrates feature representations extracted from medical texts using large language models, with structured data features derived from perioperative records of AF ablation patients. This integrated approach provides novel clinical insights into risk prognosis and enhances strategies for post-procedural management in AF ablation.

Read the detailed description

Building upon multimodal fusion and interpretable learning, this study adapts and extends methods for AF recurrence prediction. It specifically compares the impact of four open-source large language models (LLaMA-7B, Phi2-2.7B, Mistral-7B, and MedGemma-27B) on the representation of Holter ECG reports, echocardiography reports, and surgical records. A convolutional neural network is employed in the structured feature branch for representation learning and classification. Furthermore, a generative adversarial network is introduced to augment categories, mitigating the imbalance caused by the scarcity of recurrence samples. The dataset comprises multimodal information from the perioperative period and follow-up, including 28 structured features and textual data from Holter ECG reports, echocardiography reports, and surgical records. The structured features are: Age, Gender, BMI, Systolic Blood Pressure, Diastolic Blood Pressure, AF Duration, Hypertension, Coronary Artery Disease, Diabetes, CHA2DS2-VASc, HAS-BLED, AF type, LAD, LVEF, HbA1C, FPG, TC, TG, HDL, LDL, Albumin, ALT, AST, ALP, Creatine, eGFR, use of class I/III or class II antiarrhythmic drugs.

Preprocessing begins with systematic data cleaning on structured channels: for continuous variables, a combined outlier detection method based on clinically plausible range constraints and the IQR rule is used, with extreme outliers beyond the threshold truncated at quantiles while preserving order information (Supplementary A5). Missing values are handled using a multiple imputation strategy: continuous variables are predicted and imputed using regression models constructed with multiple imputation chained equations (MICE), with mean and variance adjustments to avoid shrinkage; categorical variables are imputed using mode or conditional sampling under Bayesian smoothed frequency encoding to preserve category co-occurrence relationships. To standardize scales, continuous features are z-score normalized, while retaining scaling parameters for external validation; categorical variables are subjected to target leakage-free one-hot encoding or ordinal encoding (for clearly monotonic ordinal features). All encoders are fitted within the training fold and transformed on the validation fold and test set to prevent information leakage. For text channels, lightweight cleaning and normalization are performed on dynamic electrocardiogram reports, echocardiogram reports, and surgical records, including special symbol unification, unit standardization, date and identifier de-identification, and medical abbreviation expansion; subsequently, fragment-based sentence segmentation and keyword localization are used to enhance key point density.

To implement LLM embedding + structured CNN late fusion, we construct four parallel text encoders, each fine-tuned from a pre-trained LLM (LLaMA, Phi-2, Mistral, MedGemma). Fine-tuning combines continued pre-training and instruction alignment: first, domain-specific continued pre-training is performed on de-identified dynamic electrocardiogram reports, echocardiogram reports, and surgical records from our institution to improve clinical terminology coverage and syntactic robustness; subsequently, supervised contrastive learning with a classification auxiliary objective is used to moderately update the LLMs. To balance computational power and portability, LoRA/QLoRA is used for low-rank adaptation, freezing most of the lower-layer weights and opening up partial rank parameters in the mid-to-high-layer attention blocks and word embeddings. Text representations are uniformly taken from the penultimate layer's [CLS]-equivalent pooled vector and a token-attention-based weighted average, concatenated to form a 1024-dimensional embedding, and then linearly projected to 256 dimensions to match the representation space of the structured branch. For fair comparison, the four LLMs independently train their respective text encoders and downstream fusion classification heads, while the remaining training and evaluation procedures remain consistent, resulting in four comparable multimodal models.

The structured branch uses ResNet1D as a 1D CNN backbone to learn local interactions and hierarchical features from the 30-dimensional features.Specifically, the structured vectors are stacked in a fixed order to form a "feature sequence" of length 30, which is fed into a network containing three convolutional blocks: Conv1d (channels=32, kernel size=3, stride=1) + BatchNorm + GELU + MaxPool, followed by a cascade of Conv1d(64, 3) and Conv1d(128, 3). The pooling stride of each layer is controlled to cover different receptive fields and extract cross-feature interactions. The convolutional output is then subjected to global average pooling to obtain a 256-dimensional structured embedding, which is enhanced with dropout and layer normalization to improve generalization. Considering recurrence is a relatively small minority class, a conditional tabular Generative Adversarial Network (GAN) is established within the training fold for the structured branch to perform data augmentation and balance the class distribution. We adopt a conditional WGAN-GP variant adapted to tabular data, where the generator is conditioned on class labels and encoded categorical features to generate synthetic positive samples consistent with the real joint distribution. The discriminator is trained with a Lipschitz constraint and gradient penalty to improve stability. To prevent the augmented data from introducing distribution drift and unreasonable feature combinations, we apply a triple screening process after generation: first, density filtering based on Mahalanobis distance to remove low-density outliers; second, hard constraints based on clinical rules (physiological relationships between indicators and consistency of scoring calculations); and third, an envelope screening of the positive class manifold using a one-class SVM fitted only within the training fold. By performing fold-wise augmentation within the training set, we achieve stratified sampling alignment, while maintaining the natural distribution of the validation and test sets to avoid evaluation bias.

The fusion stage follows a late fusion strategy with attention weighting. In each model instance, the 256-dimensional embedding from the structured branch is concatenated with the corresponding 256-dimensional text embedding from the LLM, forming a 512-dimensional joint representation. This representation is then fed into a multi-head scaled dot-product attention module for learnable cross-modal weighting, with the number of heads set to 4 and the key/value dimension set to 64. A gating mechanism is incorporated to suppress noisy text segments or weakly relevant structured components. The attention output is mapped to the final binary classification logit via a two-layer feedforward network (hidden dimension 256, activation GELU, dropout=0.2), and the cross-entropy loss with label-balanced weights is used as the loss function. Optimization is performed using AdamW (learning rate 2e-4, weight decay 0.01), with cosine annealing and warmup. Training employs stratified k-fold cross-validation (k=5), with patient-level splitting to prevent sample leakage. Within each fold, a validation set is used for early stopping and hyperparameter selection. Evaluation metrics include accuracy, F1-score, sensitivity, specificity, and area under the receiver operating characteristic curve (AUC-ROC), and 95% confidence intervals are reported. To ensure comparability across the four LLMs, all non-text side components, optimizer settings, training epochs, and early stopping criteria are kept consistent, with only the encoder being replaced and fine-tuned individually on the text side. During inference, deterministic forwarding with a temperature of 0 is used to obtain stable embeddings, and the maximum text length and truncation strategy are fixed to avoid bias caused by differences in context length between models.

For explainability analysis, we calculate SHAP values on the log-odds domain of the fused model output to achieve global and individual explanations. For the structured branch, we use DeepSHAP to approximate the marginal contribution of the convolutional pathway to the output, reporting the global importance and interaction effects of each original clinical feature. For the text branch, we combine attention-based token importance with SHAP's text masking estimation to locate the descriptive words driving the prediction. Based on the probability output of the optimal model, we determine the optimal threshold using the Youden's J statistic to classify patients into high-risk and low-risk groups, followed by survival analysis to compare outcome differences between the two groups.

Keywords
Atrial Fibrillation Recurrence, Large Language Model, Deep Learning, Catheter Ablation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06977516
Study groupRoleWhat they receive
Atrial Fibrillation RecurrenceAccording to the latest ACC/AHA guidelines, AF recurrence is defined as the occurrence of atrial arrhythmias (atrial tachycardia, atrial flutter, or atrial fibrillation) lasting longer than 30 s following the procedure. Recurrences occurring within 3 months postoperatively are classified as early recurrences, while those occurring after 3 months are considered late recurrences.
Non Atrial Fibrillation RecurrenceNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Late Atrial Fibrillation Recurrence

    Measured: Recurrence occurring after 3 months are considered late recurrences.

Secondary outcomes (1)
  1. Early Atrial Fibrillation Recurrence

    Measured: Recurrences occurring within 3 months postoperatively are classified as early recurrences.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 May 2025
  2. Study start15 Apr 2025
  3. Primary completion30 Jun 2025
  4. Study completion31 Aug 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
2,508 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06977516
Sponsor's protocol ID
KY-2025-068
Status last verified
Mar 2026
First submitted
11 May 2025
Last updated
12 Mar 2026
Results posted
No

Questions about this trial

What is this clinical trial studying?

An observational study of Atrial Fibrillation Recurrence, run by The Fourth Affiliated Hospital of Zhejiang University School of Medicine at 5 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Late Atrial Fibrillation Recurrence (time frame: Recurrence occurring after 3 months are considered late recurrences.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in